Imigran Sprint (Sumatriptan Succinate)

Imigran Sprint (sumatriptan) is employed to treat disorders that involve cranial vasodilation and trigeminal nerve activation.

• Migraine: rapidly alleviates pain and associated symptoms of moderate to severe migraine attacks in adults.
• Migraine with aura: reduces headache intensity and visual disturbances during aura‑associated attacks.
• Cluster headache: aborts acute cluster headache episodes, providing prompt relief for affected individuals.

• Sumatriptan succinate binds selectively to 5‑HT1B and 5‑HT1D receptors on intracranial blood vessels and trigeminal nerve terminals. Activation of 5‑HT1B receptors causes cranial vasoconstriction, while 5‑HT1D stimulation inhibits release of pro‑inflammatory neuropeptides, thereby reducing neurogenic inflammation and interrupting pain transmission pathways involved in migraine and cluster headache.

Adverse reactions may vary in frequency and severity.

Common Side Effects

• Chest discomfort or pressure
• Tingling or numbness of the face, lips, or extremities
• Warmth or flushing sensation
• Nausea or mild gastrointestinal upset

Serious or Rare Side Effects

• Coronary vasospasm or myocardial infarction
• Serotonin syndrome, especially with serotonergic agents
• Severe allergic reactions such as anaphylaxis or angioedema

Before prescribing Imigran Sprint, clinicians should evaluate patient history and potential risk factors.

• Cardiovascular assessment: review any history of coronary artery disease, angina, or uncontrolled hypertension.
• Drug contraindications: avoid use in patients with known hypersensitivity to sumatriptan or other triptans.
• Pregnancy considerations: safety has not been established; use only if potential benefit outweighs risk.
• Lactation: advise caution as drug may be excreted in breast milk.
• Concomitant serotonergic therapy: monitor for signs of serotonin syndrome.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Sumatriptan may interact with several medication classes, requiring careful management.

Major Interactions (Avoid)

• MAO inhibitors: risk of severe hypertension and serotonin syndrome.
• Other triptans or ergot alkaloids: additive vasoconstrictive effects.
• SSRIs, SNRIs, or other serotonergic agents: heightened risk of serotonin syndrome.

Moderate Interactions (Monitor Closely)

• Beta‑blockers and antihypertensives: may enhance hypotensive response.
• CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): can increase sumatriptan plasma levels.
• Oral contraceptives: may slightly raise plasma concentrations of sumatriptan.